At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
07/29/2015 Amicus Therapeutics to Announce Second Quarter 2015 Financial Results on August 5, 2015
06/29/2015 Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes
06/25/2015 Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by European Medicines Agency (EMA)
More...
Amicus Therapeutics CEO: Driving science to a cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.



Click Here to Read the Article

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy